Hyperuricemia Pipeline

DelveInsight’s, “Hyperuricemia - Pipeline Insight, 2025” report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Hyperuricemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Geography Covered

• Global coverage

 

Hyperuricemia: Understanding

Hyperuricemia: Overview

Hyperuricemia, characterized by elevated serum uric acid levels (greater than 6 mg/dL in women and 7 mg/dL in men), affects approximately 38 million Americans and is increasingly common worldwide as Western diets and lifestyles are adopted. While most individuals with hyperuricemia are asymptomatic, it can lead to conditions such as gout and nephrolithiasis. It results from increased uric acid production, decreased excretion, or both, and is linked to high cell turnover, renal dysfunction, and metabolic disorders. Additionally, hyperuricemia has been associated with an increased risk of cardiovascular disease, obesity, hypertension, and chronic kidney disease.

 

Hyperuricemia results from an imbalance in uric acid production and excretion, often due to increased purine breakdown, reduced renal excretion, or both. Uric acid, produced during the breakdown of purines, is primarily excreted by the kidneys. However, in many individuals, impaired renal excretion—often due to decreased glomerular filtration, reduced tubular secretion, or enhanced reabsorption—contributes to elevated uric acid levels. About two-thirds of uric acid is excreted by the kidneys, while the remainder is eliminated through the gastrointestinal tract. Factors such as purine-rich diets, high cell turnover (e.g., in conditions like rhabdomyolysis or hemolysis), and certain medications can accelerate uric acid production.

 

Urate transport in the kidneys is primarily regulated by the URAT1 transporter in the proximal tubule, which controls the reabsorption of uric acid. This transporter can be influenced by various factors, including organic acids, medications (e.g., niacin, cyclosporin), and dehydration, all of which can worsen hyperuricemia. Uricosuric agents that inhibit URAT1 are among the most effective treatments for reducing uric acid levels in individuals with hyperuricemia. Despite the significant contribution of renal excretion to uric acid levels, other factors, including diet and endogenous production, play a critical role in the development of this condition. 

 

Hyperuricemia is diagnosed through blood and urine tests that measure uric acid levels. A single high blood test result is not sufficient for diagnosis, and repeated measurements may be necessary. A 24-hour urine collection may also be used to assess uric acid excretion. Kidney function tests are often performed since impaired renal function can contribute to elevated uric acid levels. In cases where gout is suspected, fluid from affected joints can be analyzed for uric acid crystals to confirm the diagnosis. While hyperuricemia is common and typically asymptomatic, it is often associated with obesity and occurs more frequently in men.

 

Most patients with hyperuricemia are asymptomatic and do not require treatment, except in cases such as tumor lysis syndrome or frequent gout attacks. The American College of Rheumatology recommends treatment for patients with two or more gout attacks per year, gouty bone erosion, or hyperuricosuric nephrolithiasis. Medications for lowering uric acid levels include uricosuric agents like probenecid, xanthine oxidase inhibitors such as allopurinol and febuxostat, and recombinant uricase therapies like rasburicase and pegloticase for refractory gout. Colchicine is commonly used to manage acute gout attacks, and prophylactic use is often considered when starting uric acid-lowering therapy. The choice of treatment depends on the patient's symptoms, comorbid conditions, and response to prior therapies.

 

"Hyperuricemia- Pipeline Insight, 2025" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Hyperuricemia pipeline landscape is provided which includes the disease overview and Hyperuricemia treatment guidelines. The assessment part of the report embraces, in depth Hyperuricemia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hyperuricemia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Hyperuricemia R&D. The therapies under development are focused on novel approaches to treat/improve Hyperuricemia.

 

Hyperuricemia Emerging Drugs Chapters

This segment of the Hyperuricemia report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

 

Hyperuricemia Emerging Drugs

• AR882: Arthrosi Therapeutics

AR882 is a novel therapeutic agent designed to treat hyperuricemia, particularly in the context of gout. It functions as a highly potent and selective inhibitor of the Uric Acid Transporter 1 (URAT1), which plays a crucial role in the reabsorption of uric acid in the kidneys. By blocking URAT1, AR882 increases the excretion of uric acid into the urine, thereby reducing serum uric acid levels. This mechanism of action has the potential to alleviate symptoms associated with hyperuricemia, such as the formation of tophi and the occurrence of gout flares, offering a promising approach for managing this condition. Currently, the drug is in Phase III stage of its development for the treatment of Hyperuricemia.

 

• ABP-671: Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.

ABP-671 is an inhibitor of Urate Transporter 1 (URAT1) proteins, which are involved in reabsorption of uric acid by the kidneys. As a first line monotherapy, administered once a day in an oral tablet, ABP-671 reduces uric acid reabsorption, increasing its excretion in urine to reduce serum uric acid (sUA) levels. In long-term treatment this will reduce the number and size of tophi which will prevent gout attacks. By maintaining normal levels of sUA, the drug can also reduce the potential for complications associated with hyperuricemia, such as diabetes and heart and kidney disease. ABP-671 has demonstrated the ability to reach both sUA targets in a recent clinical trial. Approximately 93% and 77% of participants receiving ABP-671 treatment experienced reduction in sUA level to less than 6 and 5 mg/dL, respectively. Currently, the drug is in Phase III stage of its development for the treatment of Hyperuricemia.

 

• SAP-001: Shanton Pharma Pte. Ltd.

SAP-001 is a novel, clinical stage (IIb) small molecule designed to address the large and growing unmet medical needs associated with refractory and tophaceous gout. SAP-001 is the First-in-Class molecule to offer a complete solution for gout and hyperuricemia, and has the potential to become the Best-in-Class treatment for refractory and/or tophaceous gout patients and for patients that are not well controlled on allopurinol and/or febuxostat. SAP-001 is designed to effectively reduce serum uric acid levels, which is crucial for managing hyperuricemia and gout. SAP-001's approach is distinct and has shown significant efficacy in lowering serum urate levels in clinical studies. Currently, the drug is in Phase II stage of its development for the treatment of Hyperuricemia.

Further product details are provided in the report……..

 

Hyperuricemia: Therapeutic Assessment

This segment of the report provides insights about the different Hyperuricemia drugs segregated based on following parameters that define the scope of the report, such as:

 

Major  Players in Hyperuricemia

There are approx. 10+ key companies which are developing the therapies for Hyperuricemia. The companies which have their Hyperuricemia drug candidates in the most advanced stage, i.e. Phase III include, Arthrosi Therapeutics.

 

Phases

DelveInsight’s report covers around 12+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of 
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

 

Route of Administration

Hyperuricemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as 

• Oral
• Intravenous
• Subcutaneous
• Parenteral 
• Topical

Explore the evolving Hyperuricemia Market trends, key players, and future outlook.

Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer 
• Gene therapy

 

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

 

Hyperuricemia: Pipeline Development Activities 

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Hyperuricemia therapeutic drugs key players involved in developing key drugs. 

 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hyperuricemia drugs.

 

Hyperuricemia Report Insights

• Hyperuricemia Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

 

Hyperuricemia Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

 

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Hyperuricemia drugs?
• How many Hyperuricemia drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Hyperuricemia?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Hyperuricemia therapeutics? 
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies? 
• What are the clinical studies going on for Hyperuricemia and their status?
• What are the key designations that have been granted to the emerging drugs?